ClinicalTrials.gg
CompletedNCT01228370Updated Oct 5, 2012

Efficacy and Safety of Silodosin on Voiding Dysfunction Associated With Neurogenic Bladder

A Phase 4 interventional study of silodosin in Neurogenic Bladder and Voiding Dysfunction, sponsored by JW Pharmaceutical. Completed at 6 sites in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2012-10-05.

Sponsored by JW Pharmaceutical · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
95
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Study summary

Because the bladder neck and proximal urethra contain abundant α1-adrenergic receptors, α-blockers or α1-blockers are well-known to reduce bladder neck obstruction in patients with or without neurogenic bladder.

α1-blockers seem to have a potential to reduce bladder outlet resistance during voiding in patients with neurogenic bladder.

Based on these turnouts, we designed this clinical study to evaluate the clinical effect and safety of silodosin on voiding dysfunction associated with neurogenic bladder.

02

Conditions studied

  • Neurogenic Bladder
  • Voiding Dysfunction

Keywords

  • sildosin
  • neurogenic bladder
  • voiding dysfunction
03

In context

Urinary Bladder, Neurogenic

191 studies on the registry are indexed under Urinary Bladder, Neurogenic; 40 are open to participants now.

This study's enrollment of 95 is above the median of 40 across 126 interventional studies indexed under Urinary Bladder, Neurogenic.

Browse Urinary Bladder, Neurogenic studies →

Lead sponsor

JW Pharmaceutical is the lead sponsor of 77 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient who is 20 years old or over
  • Patient who is diagnosed with neurogenic bladder through urodynamic test, having urinary disorder symptoms
  • In case, patient has been taking concomitant drugs allowed for the study, only if the doses have been stable within 8 weeks from the screening visit
  • Patient who has a I-PSS score of 8 or over
  • Patient who has a QoL score of 3 or over
  • Patient who has a Qmax of below 15 mL/sec
  • Patient who has a PSA\<4.0 ng/mL or has PSA>4.0 ng/mL with no opinion of prostate cancer from
  • Patient who is willing to take the product in accordance with the protocol
  • Patient who is able to fill out questionnaire and understand requirements of the study including
  • Patient voluntarily decides to participate and signs the written consent form.

Exclusion criteria

Exclusion Criteria:

  • Patient who hs urinate at all on his/her own.
  • Patient who has a history of bladder surgery
  • Patient who has detrusor areflexia or acontractile bladder diagnosed by urodynamic test
  • Patient who has a postvoid residual urine volume(PRV) of 300 mL or greater, or has a PRV of 50% or over of the maximum bladder capacity
  • Patient who has a prostate volume of 30 mL or greater resulted from a severe benign prostatic hyperplasia(BPH) (only in case of male)
  • Patient who has urethral stricture
  • Patient who has symptomatic urinary tract infection(UTI) before screening visit
  • Patient who has a gross hematuria(except idiopathic hematuria)
  • Patient who conducts Clean Intermittent Catheterization(CIC)
  • Patient who has been taking α-blocker other than silodosin or α-agonist within 8 weeks from screening visit
  • Patient who has a Botulinum toxin injection for bladder problems within at least 1 year from screening visit
  • Patient who has severe hapatic disorders(hepatic insufficiency, cirrhosis, jaundice, hepatoma)or has a total of 2.5 mg/dL or higher or has /ALT 2.5 times higher than the normal upper limit
  • Patient who has a renal impairment with a serum creatinine 2.0 mg/dL or higher
  • Patient who has experienced severe arrhythmia, cardiac failure, myocardiac infarction, unstable angina, cerebral infarction within 6 months from screening visit
  • Patient who has orthostatic hypotention before screening visit
  • Patient who has a demanding chronic disease
  • Patient who has an allergy to drugs
  • Patient who is prohibited from taking silodosin
  • Patient who has to take drugs prohibited from the study during the clinical study
  • Patient who is pregnant or plans to be pregnant or is breastfeeding or is not practicing using medically acceptable contracenption
  • Patient who has experienced any other clinical study within 4 weeks from screening visit
  • Patient who is excluded from medical dicisions made by the investigators
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    Silodosin

    Silodosin 8mg once a day for 12 weeks

    Drug: silodosin

Interventions

  • silodosin 8mg once a day for 12 weeks

06

What researchers measure

Primary outcomes

  1. I-PSS score change after treatment

    Time frame: 12 weeks

Secondary outcomes

  1. Change in Qmax after treatment

    Time frame: 12 weeks

  2. Change in Postvoid Residual urine Volume(PRV) after treatment

    Time frame: 12 weeks

  3. Change in I-PSS Quality of Life after treatment

    Time frame: 12 weeks

07

Study locations

6 sites
  • Daegu Catholic Univ. Medical Center
    Daegu, Daegu City, Korea, Republic of
  • Daegu Fatima Hospital
    Daegu, Daegu City, Korea, Republic of
  • Keimyung Univ. Dongsan Medical Center
    Daegu, Daegu City, Korea, Republic of
  • Yeungnam Univ. Medical Center
    Daegu, Daegu City, Korea, Republic of
  • Samsung Changwon Hospital
    Changwon, Gyeongsangnam-do, Korea, Republic of
  • Ulsan Univ. Hospital
    Ulsan, Ulsan City, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2011, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2010
First posted
Oct 26, 2010
Start
Apr 2011
Primary completionActual
Jan 2012
CompletionActual
Jan 2012
Last update
Oct 5, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01228370
Lead sponsor
JW Pharmaceutical
Responsible party
Sponsor
First posted
Oct 26, 2010
Start date
Apr 2011
Primary completion
Jan 2012
Completion
Jan 2012
Last update
Oct 5, 2012

Study contacts

Duk-Yoon Kim
principal investigator · Daegu Catholic University Medical Center
Chul-Hee Park
principal investigator · Keimyung Univ. Dongsan Medical Center
Hee-Chang Jung
principal investigator · Yeungnam Univ. Medical Center
Kyung-Hyun Moon
principal investigator · Ulsan Univ. Hospital
Tae-Hee Oh
principal investigator · Samsung Changwon Hospital
Jae-Soo Kim
principal investigator · Daegu Fatima Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Silodosin

Start the discussion